Under the original proposed formulary change, adult patients currently taking the reference infliximab would be switched to the biosimilar.
Excellus BlueCross BlueShield (BCBS) announced in January 2018 that it would switch its formulary coverage for adult Crohn disease and ulcerative colitis treatment from the reference infliximab (Remicade, sold by Janssen) to biosimilar infliximab (Inflectra, sold by Pfizer).
Under the original proposed formulary change, adult patients currently taking the reference infliximab would be switched to the biosimilar.
According to Excellus BCBS’ Pharmacy Management Drug Policy, this change would only apply to adult patients due to the reference infliximab product being the only one with an FDA-approved indication for the treatment of pediatric ulcerative colitis. The pediatric ulcerative colitis indication is protected by orphan exclusivity through September of this year.
However, a month after receiving some pushback from patients, Excellus made a second announcement that, after further consideration, it had modified the criteria requirements for prescribing the biosimilar in place of the reference product.
The updated proposal mandates that for adult patients enrolled in its commercial, exchange, Medicaid managed care, and Child Health Plus plans who are newly initiating infliximab therapy, the biosimilar is the preferred drug. In the instance that the biosimilar is ineffective for the patient, the request for medical necessity review is allowed for an alternate therapy.
However, a nonmedical switch no longer applies to members who are currently prescribed the reference product, who may continue with the reference therapy, though Excellus does encourage prescribers to consider switching patients.
Around the time of the updated formulary change, Mona Chitre, PharmD, chief pharmacy officer and vice president of medical operations and health innovations at Excellus, wrote an editorial published in the Oneida Daily Dispatch that discussed the lack of competition among US drug makers.
“Per capita healthcare spending in many industrialized nations is less than it is here in the United States, but in many cases, those countries have healthcare outcomes that are similar to ours. Contributing to this parity in quality but disparity in spending is the lack of approved biosimilar medications to compete here with high-priced, brand-name biologics,” said Chitre.
Chitre writes that the average annual cost of reference infliximab in the United States is $28,000 per patient. In fact, over the past 5 years, Johnson & Johnson, the developer of the reference, raised the price by 57% with many of those years seeing 2 price increases.
Lower-cost infliximab biosimilars have been available in Europe since 2013, 2 of which are FDA-approved: Inflectra and Renflexis (sold by Merck).
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Risk-Adjusted NPV Framework for Biosimilars Shows Key Investment Drivers
April 7th 2025Early market entry, manufacturing efficiency, and market share are critical to biosimilar development success, while technical complexity and competition heavily impact returns, according to a study presenting a risk-adjusted net present value (NPV) analysis framework.